Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Investigational compound faldaprevir shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C

In the Phase III clinical trial STARTVerso™1, up to 80% of patients treated with faldaprevir+ and PegIFN/RBV achieved viral cure (SVR12).

Published
24 April 2013
From
Boehringer-Ingelheim press release
Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Presented at EASL 23-28 April in Amsterdam Read more: Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Pres

These primary efficacy and safety results from two global phase III studies demonstrate that use of the investigational protease inhibitor simeprevir led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease, when administered once daily with pegylated interferon and ribavirin.

Published
24 April 2013
From
Medivir press release
AbbVie hepatitis C drugs knock out virus at eight weeks

A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.

Published
24 April 2013
From
Yahoo News
Bristol-Myers oral hepatitis C regimen looks competitive -study

The combination therapy, which involves three direct acting antiviral drugs that each attack different targets needed for replication of the hepatitis virus, achieved cure rates as high as 94 percent when given for either 12 weeks or 24 weeks, according to results of the small study.

Published
24 April 2013
From
Reuters
The Hepatitis C Drug Pipeline Report: A Groundswell to Become a Sea Change

Frantic competition between the major pharmaceutical players has accelerated progress on new hepatitis C virus (HCV) therapies to a breakneck speed.

Published
19 April 2013
From
Hep: Your Guide to Hepatitis
Roche to commercialize Hepatitis C drug in China with Ascletis

Swiss drugmaker Roche Holding AG said it had teamed up with biotech firm Ascletis to develop and commercialize its investigative drug danoprevir in China for the treatment of the Hepatitis-C virus.

Published
15 April 2013
From
Yahoo! News
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C

Sofosbuvir Would Form Basis of First All-Oral Regimen for HCV Genotype 2 and 3 Patients, and Interferon-Sparing Regimen for Genotype 1 Patients.

Published
09 April 2013
From
Gilead press release
Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS' investigational NS5A replication complex inhibitor daclatasvir.

Published
08 April 2013
From
Vertex press release
Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C

Filing Based on Phase 3 Data in Treatment-Naïve and Treatment-Experienced Patients with Compensated Liver Disease.

Published
02 April 2013
From
Janssen press release
Hepatitis C drug goes after patients’ RNA

The new drug, called miravirsen, binds to microRNA-122, sequesters it and indirectly thwarts viral replication, says study coauthor Harry Janssen, a hepatologist and physician at the University of Toronto. Janssen and colleagues report the findings March 27 in the New England Journal of Medicine.

Published
28 March 2013
From
Science News

Filter by country